Tuberculose et VIH : drame de l’Afrique

Dominique Labie

doi:10.1051/medsci/20062210878

Home

All issues

Volume 22 / No 10 (Octobre 2006)

Med Sci (Paris), 22 10 (2006) 878-880

References

Free Access

Issue		Med Sci (Paris) Volume 22, Number 10, Octobre 2006


Page(s)		878 - 880
Section		Repères
DOI		https://doi.org/10.1051/medsci/20062210878
Published online		15 October 2006

Corbett EI, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa : opportunities, challenges, and change in the of antiretroviral treatment. Lancet 2006; 367 : 926–37. [Google Scholar]
World Health Organization. Global tuberculosis control : surveillance, planning, financing. WHO report 2005. WHO/HTM/TB/2005.349. Genève : OMS, 2005. [Google Scholar]
Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367 : 938–40. [Google Scholar]
Perkins MD, Roscigno G, Zumla A. Progress towards improved tuberculosis diagnostics for developing countries. Lancet 2006; 367 : 942–3. [Google Scholar]
Becerra MC, Pachao-Torreblanca I, Bayona J, et al. Expanding tuberculosis case detection by screening households contacts. Publ Health Rep 2005; 120 : 271–7. [Google Scholar]
Harries AD, Chimzizi R, Zachariah R. Safety, effectiveness, and outcomes of concomitant use of highly active antiretroviral therapy with drugs for tuberculosis in resource-poor settings. Lancet 2006; 367 : 944–5. [Google Scholar]
Pedral-Sampaio DB, Alves CR, Netto EM, et al. Efficacy and safety of efavirenz in HIV patients on rifampin for tuberculosis. Braz J Infect Dis 2004; 8 : 211–6. [Google Scholar]
Onyebujoh P, Rodriguez W, Mwaba P. Priorities in tuberculosis research. Lancet 2006; 367 : 940–1. [Google Scholar]
Spigelman M, Gillespie S. Tuberculosis drug development pipelines : progress and hope. Lancet 2006; 367 : 945–7. [Google Scholar]
Doherty TM, Rook G. Progress and hindrances in tuberculosis vaccine development. Lancet 2006; 367 : 947–9. [Google Scholar]
Raviglione MC, Uplekar MW. WHO’s new stop TB strategy. Lancet 2006; 367 : 952–5 [Google Scholar]
Squire SB, Obasi A, Nhlema-Simwaka B. The Global plan to stop TB : a unique opportunity to address poverty and the Millenium development goals. Lancet 2006; 367 : 955–7. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.

[1] Corbett EI, Marston B, Churchyard GJ, De Cock KM. Tuberculosis in sub-Saharan Africa : opportunities, challenges, and change in the of antiretroviral treatment. Lancet 2006; 367 : 926–37. [Google Scholar]

[2] World Health Organization. Global tuberculosis control : surveillance, planning, financing. WHO report 2005. WHO/HTM/TB/2005.349. Genève : OMS, 2005. [Google Scholar]

[3] Dye C. Global epidemiology of tuberculosis. Lancet 2006; 367 : 938–40. [Google Scholar]

[4] Perkins MD, Roscigno G, Zumla A. Progress towards improved tuberculosis diagnostics for developing countries. Lancet 2006; 367 : 942–3. [Google Scholar]

[5] Becerra MC, Pachao-Torreblanca I, Bayona J, et al. Expanding tuberculosis case detection by screening households contacts. Publ Health Rep 2005; 120 : 271–7. [Google Scholar]

[6] Harries AD, Chimzizi R, Zachariah R. Safety, effectiveness, and outcomes of concomitant use of highly active antiretroviral therapy with drugs for tuberculosis in resource-poor settings. Lancet 2006; 367 : 944–5. [Google Scholar]

[7] Pedral-Sampaio DB, Alves CR, Netto EM, et al. Efficacy and safety of efavirenz in HIV patients on rifampin for tuberculosis. Braz J Infect Dis 2004; 8 : 211–6. [Google Scholar]

[8] Onyebujoh P, Rodriguez W, Mwaba P. Priorities in tuberculosis research. Lancet 2006; 367 : 940–1. [Google Scholar]

[9] Spigelman M, Gillespie S. Tuberculosis drug development pipelines : progress and hope. Lancet 2006; 367 : 945–7. [Google Scholar]

[10] Doherty TM, Rook G. Progress and hindrances in tuberculosis vaccine development. Lancet 2006; 367 : 947–9. [Google Scholar]

[11] Raviglione MC, Uplekar MW. WHO’s new stop TB strategy. Lancet 2006; 367 : 952–5 [Google Scholar]

[12] Squire SB, Obasi A, Nhlema-Simwaka B. The Global plan to stop TB : a unique opportunity to address poverty and the Millenium development goals. Lancet 2006; 367 : 955–7. [Google Scholar]